title: Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.
abstract: BACKGROUND
  The aim of this study was to evaluate prognostic factors including efficacy of postoperative chemotherapy in Japanese patients with uterine carcinosarcoma.
  
  
  METHODS
  We conducted a retrospective survey of seven medical facilities in the Tohoku Gynecologic Cancer Unit.
  
  
  RESULTS
  A total of 45 patients who had undergone hysterectomy and bilateral salpingo-oophorectomy were enrolled. No significant difference was observed in overall survival according to patient age (≤ 50 years vs >50 years) or retroperitoneal lymphadenectomy (performed vs. not performed). However, the International Federation of Gynecology and Obstetrics stage (stage I/II vs stage III/IV) and postoperative chemotherapy (provided vs not provided) were significant prognostic factors in both univariate and multivariate analyses for the 25-month median follow-up period.
  
  
  CONCLUSIONS
  Our results revealed that postoperative chemotherapy should be considered for all uterine carcinosarcoma stages in Japanese patients.
authors.affiliation: Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Ai
authors.initials: A
authors.lastname: Otsuki
authors.forename: Takeo
authors.initials: T
authors.lastname: Otsuki
authors.forename: Hideki
authors.initials: H
authors.lastname: Tokunaga
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Niikura
authors.forename: Satoru
authors.initials: S
authors.lastname: Nagase
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Masafumi
authors.initials: M
authors.lastname: Toyoshima
authors.forename: Hiroki
authors.initials: H
authors.lastname: Utsunomiya
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Mizunuma
authors.forename: Naoki
authors.initials: N
authors.lastname: Sato
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Terada
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakahara
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ohta
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Yamada
authors.forename: Toru
authors.initials: T
authors.lastname: Tase
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishiyama
authors.forename: Keiya
authors.initials: K
authors.lastname: Fujimori
authors.forename: Tadao
authors.initials: T
authors.lastname: Takano
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Takahashi
authors.forename: Yoh
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yaegashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002296:Carcinosarcoma / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery